Anti-CTLA-4 and RFA in the B16-OVA model have been shown to augment the anti-tumor effect of splenocytes, which resulted in long-lasting tumor protection (22) and regulatory T cell depletion in addition to increased tumor-specific T cell numbers, therefore protecting mice from tumor challenges (113). The gene discussed is CTLA4; the disease is neoplasm.